TNDM Tandem Diabetes Care (TNDM) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001438133
Congress · 1Form 144 · 3
Insider buyers, 180 days
0
Funds added, last quarter
147
13F, latest reported quarter
Conversions, 180 days
42
Codes C/M, not in net · $0 priced
What the filings say about TNDM
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-29
Planned sales (Form 144), 90 days
$41.4K
3 notices
Tandem Diabetes Care insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for TANDEM DIABETES CARE INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Mar 5, 2026.
- The trade is 0.5% of the 37,656 shares held after it.
- No other insider sold within 30 days.
- 147 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CHIEF COMMERCIAL OFFICER Novara Mark David sold about $4.3K of TNDM on Mar 17, 2026, the largest insider sale at the company since 2024; 147 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 15, 2024.
- The trade is 0.0% of the 35,969 shares held after it.
- No other insider sold within 30 days.
- 147 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CHIEF COMMERCIAL OFFICER Novara Mark David sold about $46 of TNDM on Mar 5, 2026, the largest insider sale at the company since 2024; 147 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on May 9, 2022.
- The trade is 9.4% of the 106,327 shares held after it.
- 1 other insider bought within 30 days.
- 147 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT & CEO Sheridan John F bought about $102.3K of TNDM on Aug 11, 2025; 1 other insider bought within 30 days and 147 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (5 buys, 8 sales), the last on Nov 8, 2023.
- -12.3% median (+2.1% mean) 90-day return after 4 previous buys.
- The trade is 53.6% of the 25,580 shares held after it.
- 1 other insider bought within 30 days.
- 147 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought about $149.4K of TNDM on Aug 8, 2025; 1 other insider bought within 30 days and 147 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 10,538 shares held after it.
- No other insider bought within 30 days.
- 147 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Operating Officer Kyrillos Jean-Claude bought about $190.9K of TNDM on Mar 7, 2025, the largest insider purchase at the company since 2023; 147 funds added in the latest 13F quarter.118 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
147 funds bought in last quarter
more than 75% of Medical Devices
Revenue
+7.9% year over year
below 56% of Medical Devices
Margin
-20.2% net margin
below 53% of Medical Devices
Buybacks
no share repurchases reported
Short interest
23.7% of the float short (float per yahoo 2026-10-27) · 6.9 days to cover · settled 2026-10-15
more than 99% of Medical Devices
What changed in the last 30 days
Oct 27Director CHRISTOPHER TWOMEY filed to sell $32.1K by Oct 27 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch TNDM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+31.1%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TNDM: institutional holders (13F)
13F holdings, latest reported quarter
11,583,125 sh
$174.8M
5,100,000 sh
$77.0M
4,299,667 sh
$64.9M
3,383,553 sh
$51.1M
3,096,536 sh
$46.7M
Congress trades in TNDM
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Bought 2025-09-22 · disclosed 23 days later
$1,001 - $15,000
Sold 2025-03-19 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-03-04 · disclosed 34 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TNDM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
CHRISTOPHER TWOMEY
Filed 2026-10-27
$32.1K
MARK NOVARA
Filed 2026-09-17
$6.3K
MARK NOVARA
Filed 2026-08-18
$2.9K
TNDM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Advent Convertible Bond ETF
$578.5K position · as of 2026-05-31
1.8%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.3M position · as of 2026-06-30
1.5%
Meridian Small Cap Growth Fund
$4.1M position · as of 2026-06-30
1.5%
Meridian Growth Fund
$7.3M position · as of 2026-06-30
1.3%
Global X HealthTech ETF
$296.2K position · as of 2026-05-31
1.2%
WESTWOOD ALTERNATIVE INCOME FUND
$2.0M position · as of 2026-07-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
16 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
16
Not applicable
1 active
What changed recently
PS230005 Control-IQ 1.5 Post-Approval Study
2026-09-02 · Active Not Recruiting → Completed
,
Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in Peopl
2026-09-01 · Active Not Recruiting → Completed
Not applicable
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · John F. Sheridan
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.9M
$2.9M
$2.0M
-77%
-1%
2024
$8.5M
$6.8M
$1.9M
-40%
+5%
2023
$4.7M
$1.5M
$1.5M
-50%
+6%
2022
$6.4M
-$8.3M
$1.7M
-25%
-0%
2021
$5.7M
$16.4M
$1.6M
+153%
+25%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 147 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $41.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
TNDM financials
Revenue growth
+7.9%
XBRL, annual
Net margin
-20.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TNDM
| FY Dec 2025 | $1.0B |
| FY Dec 2024 | $940.2M |
| FY Dec 2023 | $747.7M |
| FY Dec 2022 | $801.2M |
| FY Dec 2021 | $702.8M |
| Jun 2026 | $254.6M |
| Mar 2026 | $247.2M |
| Dec 2025 | $290.4M |
| Sep 2025 | $249.3M |
| Jun 2025 | $240.7M |
| Mar 2025 | $234.4M |
| Dec 2024 | $282.6M |
| Sep 2024 | $244.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TNDM
| FY Dec 2025 | -20.2% |
| FY Dec 2024 | -10.2% |
| FY Dec 2023 | -29.8% |
| FY Dec 2022 | -11.8% |
| FY Dec 2021 | +2.2% |
| Jun 2026 | -8.3% |
| Mar 2026 | -8.2% |
| Dec 2025 | -0.2% |
| Sep 2025 | -8.5% |
| Jun 2025 | -21.8% |
| Mar 2025 | -55.7% |
| Dec 2024 | +0.3% |
| Sep 2024 | -9.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$26.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TNDM
| FY Dec 2025 | -$29.7M |
| FY Dec 2024 | $5.0M |
| FY Dec 2023 | -$58.6M |
| FY Dec 2022 | $16.4M |
| FY Dec 2021 | $97.2M |
| Jun 2026 | -$38.7M |
| Mar 2026 | $4.8M |
| Dec 2025 | $3.1M |
| Sep 2025 | $4.2M |
| Jun 2025 | -$15.7M |
| Mar 2025 | -$21.2M |
| Dec 2024 | $7.6M |
| Sep 2024 | $21.5M |
At each fiscal year end
Single quarter
Debt to equity
4.93x
long-term 2026-06-30 plus current 2024-12-31 (18 months older than the period end); equity 2026-06-30
Debt to equity TNDM
| FY Dec 2025 | 2.26x |
| FY Dec 2024 | 1.33x |
| FY Dec 2023 | 0.91x |
| FY Dec 2022 | 0.64x |
| FY Dec 2021 | 0.65x |
| Jun 2026 | 4.93x |
| Mar 2026 | 4.85x |
| Dec 2025 | 2.26x |
| Sep 2025 | 2.63x |
| Jun 2025 | 2.62x |
| Mar 2025 | 2.25x |
| Dec 2024 | 1.33x |
| Sep 2024 | 1.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.01x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-12-31 (18 months older than the period end)
Cash flow to debt TNDM
| FY Dec 2025 | -0.03x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | -0.11x |
| FY Dec 2022 | 0.18x |
| FY Dec 2021 | 0.40x |
| Jun 2026 | -0.01x |
| Mar 2026 | 0.03x |
| Dec 2025 | -0.03x |
| Sep 2025 | -0.03x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.04x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-48.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TNDM
| FY Dec 2025 | -97.9% |
| FY Dec 2024 | -33.3% |
| FY Dec 2023 | -59.1% |
| FY Dec 2022 | -21.7% |
| FY Dec 2021 | +3.9% |
| Jun 2026 | -48.0% |
| Mar 2026 | -65.7% |
| Dec 2025 | -97.9% |
| Sep 2025 | -109.7% |
| Jun 2025 | -111.9% |
| Mar 2025 | -92.3% |
| Dec 2024 | -33.3% |
| Sep 2024 | -46.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-6.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TNDM
| FY Dec 2025 | -22.1% |
| FY Dec 2024 | -10.0% |
| FY Dec 2023 | -22.2% |
| FY Dec 2022 | -9.7% |
| FY Dec 2021 | +1.9% |
| Jun 2026 | -6.2% |
| Mar 2026 | -9.1% |
| Dec 2025 | -22.1% |
| Sep 2025 | -22.2% |
| Jun 2025 | -22.7% |
| Mar 2025 | -19.7% |
| Dec 2024 | -10.0% |
| Sep 2024 | -13.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TNDM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +3.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-6.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TNDM
| FY Dec 2025 | -27.6% |
| FY Dec 2024 | -13.4% |
| FY Dec 2023 | -28.4% |
| FY Dec 2022 | -11.2% |
| FY Dec 2021 | +3.3% |
| Jun 2026 | -6.0% |
| Mar 2026 | -10.9% |
| Dec 2025 | -27.6% |
| Sep 2025 | -29.7% |
| Jun 2025 | -30.2% |
| Mar 2025 | -25.8% |
| Dec 2024 | -13.4% |
| Sep 2024 | -18.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TNDM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 654.43x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.9B
market value at close 2026-10-27 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
Enterprise value TNDM
| FY Dec 2025 | $1.8B |
| FY Dec 2024 | $2.6B |
| FY Dec 2023 | $2.2B |
| FY Dec 2022 | $3.0B |
| FY Dec 2021 | $9.8B |
| Jun 2026 | $1.6B |
| Mar 2026 | $1.8B |
| Dec 2025 | $1.8B |
| Sep 2025 | $1.1B |
| Jun 2025 | $1.5B |
| Mar 2025 | $1.6B |
| Dec 2024 | $2.6B |
| Sep 2024 | $3.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-2.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield TNDM
| FY Dec 2025 | -2.0% |
| FY Dec 2024 | +0.2% |
| FY Dec 2023 | -3.0% |
| FY Dec 2022 | +0.6% |
| FY Dec 2021 | +1.0% |
| Jun 2026 | -2.6% |
| Mar 2026 | -0.3% |
| Dec 2025 | -2.0% |
| Sep 2025 | -3.1% |
| Jun 2025 | -0.6% |
| Mar 2025 | -0.3% |
| Dec 2024 | +0.2% |
| Sep 2024 | -0.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TNDM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.0B | $940.2M | $747.7M | $801.2M |
| Gross profit | $546.0M | $489.6M | $367.7M | $413.0M |
| Operating income | -$187.3M | -$99.1M | -$233.2M | -$92.8M |
| Net income | -$204.7M | -$96.0M | -$222.6M | -$94.6M |
| EPS (diluted) | -3.04 | -1.47 | -3.43 | -1.47 |
| Operating cash flow | -$9.7M | $24.2M | -$31.8M | $50.5M |
| Cash | $90.6M | $69.2M | $58.9M | $172.5M |
| Long-term debt | $310.0M | $308.3M | $285.0M | $283.2M |
| Buybacks | $0 | $30.0M | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
TNDM Stock Sonar score 5/7 axes
Find similar shapesCompareTNDM ranks highest on institutional and government (66th percentile) and profitability (54th), and lowest on risk and compliance (16th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TNDM filings, in plain words
Have members of Congress traded TNDM?
Yes. In the year to 2026-10-28, 1 House member disclosed buying TNDM and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29.
Are there planned insider sales of TNDM?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $41.4K of stock; the latest, by CHRISTOPHER TWOMEY, was filed 2026-10-27.
Read the full summary
In the year to 2026-10-28, 1 member of Congress disclosed buying TNDM and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $41.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
